# Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

> **NCT01392443** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Primary Myelofibrosis (MF)
- Post-Polycythemia Vera (PV) MF
- Post-Essential Thrombocythemia (ET) MF

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01392443
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-14
- **Primary completion:** 2017-10-31
- **Final completion:** 2017-10-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392443, "Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01392443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*